PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.35%
Revenue growth under 50% of AVGO's 81.03%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.67%
Gross profit growth at 75-90% of AVGO's 10.08%. Bill Ackman would demand operational improvements to match competitor gains.
19.59%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
19.65%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
20.94%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
22.22%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
22.58%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-1.03%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.10%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.21%
Dividend reduction while AVGO stands at 7.78%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
78.45%
OCF growth above 1.5x AVGO's 25.10%. David Dodd would confirm a clear edge in underlying cash generation.
84.17%
FCF growth above 1.5x AVGO's 23.03%. David Dodd would verify if the firm’s strategic investments yield superior returns.
75.81%
10Y revenue/share CAGR at 50-75% of AVGO's 147.44%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
43.93%
5Y revenue/share CAGR under 50% of AVGO's 197.85%. Michael Burry would suspect a significant competitive gap or product weakness.
9.01%
3Y revenue/share CAGR under 50% of AVGO's 107.08%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
139.61%
10Y OCF/share CAGR under 50% of AVGO's 347.97%. Michael Burry would worry about a persistent underperformance in cash creation.
96.33%
Below 50% of AVGO's 762.99%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
31.16%
3Y OCF/share CAGR at 50-75% of AVGO's 45.06%. Martin Whitman would suspect weaker recent execution or product competitiveness.
139.45%
Positive 10Y CAGR while AVGO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
81.78%
Positive 5Y CAGR while AVGO is negative. John Neff might view this as a strong mid-term relative advantage.
48.33%
Positive short-term CAGR while AVGO is negative. John Neff would see a clear advantage in near-term profit trajectory.
32.52%
Equity/share CAGR of 32.52% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
31.35%
Below 50% of AVGO's 248.22%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
2.49%
Below 50% of AVGO's 63.02%. Michael Burry suspects a serious short-term disadvantage in building book value.
1346.20%
Dividend/share CAGR of 1346.20% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
173.68%
Dividend/share CAGR of 173.68% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
132.62%
3Y dividend/share CAGR at 50-75% of AVGO's 226.51%. Martin Whitman might see a weaker short-term approach to distributing cash.
-3.27%
Firm’s AR is declining while AVGO shows 84.95%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.40%
Inventory shrinking or stable vs. AVGO's 60.13%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
0.51%
Asset growth well under 50% of AVGO's 180.63%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
1.09%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-0.06%
We’re deleveraging while AVGO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.87%
Our R&D shrinks while AVGO invests at 110.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.91%
We cut SG&A while AVGO invests at 104.48%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.